BioLife Solutions (NASDAQ:BLFS) Posts Quarterly Earnings Results, Beats Expectations By $0.32 EPS

BioLife Solutions (NASDAQ:BLFS - Get Free Report) posted its quarterly earnings results on Monday. The medical equipment provider reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.32, RTT News reports. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to analysts' expectations of $21.73 million. During the same quarter in the prior year, the business earned ($0.21) EPS. BioLife Solutions updated its FY 2025 guidance to EPS.

BioLife Solutions Price Performance

BioLife Solutions stock traded down $0.97 during mid-day trading on Friday, reaching $25.83. 608,317 shares of the company were exchanged, compared to its average volume of 283,669. The firm has a market cap of $1.20 billion, a PE ratio of -24.37 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a fifty day simple moving average of $26.66 and a 200-day simple moving average of $25.49. BioLife Solutions has a 12 month low of $14.84 and a 12 month high of $29.55.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BLFS. HC Wainwright raised their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday. Benchmark restated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum increased their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a report on Wednesday, January 8th. Finally, KeyCorp upped their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.86.

Remove Ads

Insider Activity

In other BioLife Solutions news, EVP Aby J. Mathew sold 7,604 shares of the firm's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now directly owns 276,315 shares of the company's stock, valued at $7,551,688.95. This trade represents a 2.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Troy Wichterman sold 987 shares of the company's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares of the company's stock, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 11,978 shares of company stock worth $322,724. 2.20% of the stock is currently owned by company insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.